Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002889 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00002889 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 180 participants.
The verdict
NCT00002889, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
RATIONALE: Imaging procedures such as MRI may improve the ability to determine the response of prostate tumors to therapy. PURPOSE: Phase II trial to study MRI results in patients with prostate cancer that has been treated with radiation therapy plus androgen suppression therapy.
Interventions
- DRUG leuprolide acetate
- DRUG goserelin
- DRUG flutamide
- RADIATION low-LET photon therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 1997-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002889
The ClinicalTrials.gov registry entry for NCT00002889 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which leuprolide acetate is the first listed.
NCT00002889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002889 about?
NCT00002889 is a clinical study titled "Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer". RATIONALE: Imaging procedures such as MRI may improve the ability to determine the response of prostate tumors to therapy. PURPOSE: Phase II trial to study MRI results in patients with prostate cancer that has been treated with radiation therapy plus androgen suppression therapy.
What is the current status of trial NCT00002889?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 1997-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00002889?
The interventions under investigation include: leuprolide acetate (DRUG), goserelin (DRUG), flutamide (DRUG), low-LET photon therapy (RADIATION).
Who is sponsoring clinical trial NCT00002889?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.